IND Approved for Semaglutide-Based Long-Acting Injectable "TION-L002"

Daewoong Pharmaceutical said on November 19 that the Ministry of Food and Drug Safety had approved the investigational new drug (IND) application for a Phase 1 clinical trial of TION-L002, a once-monthly, long-acting candidate for obesity treatment that it is co-developing with Tion Lab Therapeutics.


A once-monthly, long-acting semaglutide injection being co-developed by Daewoong Pharmaceutical and TionLab Therapeutics. Daewoong Pharmaceutical

A once-monthly, long-acting semaglutide injection being co-developed by Daewoong Pharmaceutical and TionLab Therapeutics. Daewoong Pharmaceutical

View original image

TION-L002 is a long-acting injectable being developed based on semaglutide, an active ingredient used to treat obesity and diabetes. The goal is to extend the dosing interval for existing once-weekly semaglutide products to once a month. If development is successful, the number of injections per year could be reduced from 52 to 12.


In the Phase 1 trial, the two companies plan to evaluate TION-L002's safety and pharmacokinetic characteristics and compare it with a control drug to assess the potential of developing a long-acting formulation. Based on the trial results, they also plan to seek global partners and pursue entry into overseas markets.


TION-L002 uses Daewoong Pharmaceutical's CURE® drug-delivery platform and Tion Lab Therapeutics' Quject®Sphere. By combining the two companies' platforms, the formulation is designed to prevent the drug from being released all at once immediately after injection and instead release it at a steady rate over an extended period.


Daewoong Pharmaceutical's CURE is a technology that produces uniform drug particle sizes through an inlet-nozzle process. Tion Lab Therapeutics' Quject®Sphere is a technology that coats drug particles with a specialized composition to suppress the initial release of the drug.


Deoksu Im, CEO of Tion Lab Therapeutics, said, "TION-L002, which we have been developing in collaboration with Daewoong Pharmaceutical, has entered the clinical stage in earnest. Building on the formulation technologies of both companies, we will develop a long-acting obesity treatment that is expected to deliver effects comparable to existing treatments with just one dose a month."



Seongsu Park, CEO of Daewoong Pharmaceutical, said, "Approval of the IND for this long-acting injectable will further strengthen our obesity-treatment portfolio. Based on data from clinical trials in Korea, we will expand our global partnerships and accelerate development to provide patients around the world with more convenient treatment options."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing